Angiotensin II type I receptor antagonist suppresses proteinuria and glomerular lesions in experimental nephritis

European Journal of Pharmacology

Volumn 374, Issue 1, 1999, Pages 93-101

  Nagamatsu, Tadashi ^a   Hayashi, Kazumi ^a   Oka, Tatsuya ^a   Suzuki, Yoshio ^a  

^a MEIJO UNIVERSITY   (Japan)

Author keywords

Angiotensin AT1 receptor antagonist; Anti glomerular basement membrane antibody associated nephritis; Extracellular matrix protein; Proliferation; Transformed cell

Indexed keywords

4,5,6,7 TETRAHYDRO 8 OXO 2 PROPYL 1 [[2' (1H TETRAZOL 5 YL)BIPHENYL 4 YL]METHYL]CYCLOHEPTIMIDAZOLE; ALPHA ACTIN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; CAPTOPRIL; CYCLINE; DESMIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRONECTIN; GLOMERULUS BASEMENT MEMBRANE ANTIBODY; NITROGEN; PROTEOGLYCAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; GLOMERULONEPHRITIS; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROTEINURIA; RAT; UREA NITROGEN BLOOD LEVEL;

ANIMALS; EXTRACELLULAR MATRIX PROTEINS; GLOMERULONEPHRITIS; IMIDAZOLES; IMMUNOGLOBULIN G; KIDNEY GLOMERULUS; MALE; PROTEINURIA; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ANGIOTENSIN; TETRAZOLES; TRANSFORMING GROWTH FACTOR BETA;

EID: 0033028270     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(99)00276-9     Document Type: Article

References (45)

1. Anderson P., Do Y.S., Hsueh W.A. Angiotensin II causes mesangial cell hypertrophy. Hypertension. 21:1993;29-35.
2. Bernstein K.E., Berk B.C. The biology of angiotensin II receptors. Am. J. Kidney Dis. 22:1993;745-754.
3. Border W.A., Ruoslahti E. Transforming growth factor-β induces extracellular matrix formation in glomerulonephritis. Cell Differ. Dev. 32:1990;425-431.
4. Border W.A., Okuda S., Languino L.A., Ruoslahti E. Transforming growth factor-β regulates productions of proteoglycans by mesangial cells. Kidney Int. 37:1990;689-695.
5. Brunner H.R. ACE inhibitors in renal disease. Kidney Int. 42:1992;463-479.
6. Grandaliano G., Valente A.J., Rozek M.M., Abboud H.E. Gamma interferon stimulates monocyte chemotactic protein (MCP-1) in human mesangial cells. J. Lab. Clin. Med. 123:1994;282-289.
7. Hattori T., Nagamatsu T., Ito M., Suzuki Y. Contribution of ED-1- and CD8-positive cells to the development of crescentic anti-GBM nephritis in rats. Jpn. J. Nephrol. 36:1994;1228-1239.
8. Hayashi K., Nagamatsu T., Ito M., Hattori T., Suzuki Y. Acteoside, a component of Stachys Sieboldii MIQ, may be a promising antinephritic agent: (2). Effect of acteoside on leukocyte accumulation in the glomeruli of nephritic rats. Jpn. J. Pharmacol. 66:1994;47-52.
9. Hayashi K., Nagamatsu T., Ito M., Hattori T., Suzuki Y. Acteoside, a component of Stachys Sieboldii MIQ, may be a promising antinephritic agent: effect of acteoside on crescentic-type anti-GBM nephritis in rats. Jpn. J. Pharmacol. 65:1994;143-151.
10. Ishidoya S., Morrissey J., McCracken R., Reyes A., Klahr S. Angiotensin II receptor antagonist ameliorates renal tublointerstitial fibrosis caused by unilateral obstruction. Kidney Int. 47:1995;1285-1294.
11. Kagami S., Border W.A., Miller D.E., Noble N.A. Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-β expression in rat glomerular mesangial cells. J. Clin. Invest. 93:1994;2413-2437.
12. Kai T., Kino H., Ishikawa K. Role of the renin-angiotensin system in cardiac hypertrophy and renal glomerular sclerosis in transgenic hypertensive mice carrying both human renin and angiotensinogen genes. Hypertens. Res. 21:1998;39-46.
13. Keane W.F., Raij L. Relationship among altered glomerular barrier perm-selectivity, angiotensin II, and mesangial uptake of macromolecules. Lab. Invest. 52:1985;599-604.
14. Ketteler M., Noble N.A., Border W.A. Increased expression of transforming growth factor-β in renal disease. Curr. Opin. Nephrol. Hypertens. 3:1994;446-452.
15. Kingsbury F.B., Clark C.P., Williams G., Post A.L. The rapid determination of albumin in urine. J. Lab. Clin. Med. 11:1926;981-989.
16. 1 angiotensin II receptors in renal ischemic injury. Am. J. Physiol. 274:1998;F79-F90.
17. Meister B., Liooildt A., Bunnemann B., Inagami T., Ganten D., Fuxe K. Cellular expression of angiotensin type-1 receptor mRNA in the kidney. Kidney Int. 44:1993;331-336.
18. Mimran A., Insura A., Ribstein J., Bringer J., Monnier L. Comparative effect of captopril and nifedipine in normotensive patient with incipient diabetic nephropathy. Diabetes Care. 11:1988;850-853.
19. Mochizuki S., Sato T., Furuta K., Hase K., Ohkura Y., Fukai C., Kosakai K., Wakabayashi S., Tomiyama A. Pharmacological properties of KT3-671, a novel nonpeptide angiotensin II receptor antagonist. J. Cardiovasc. Pharmacol. 25:1995;22-29.
20. Morelli E., Loon N., Meyer T.W., Peters W., Mayers B.D. Effects of converting-enzyme inhibition on barrier function in diabetic glomerulopathy. Diabetes. 39:1990;76-82.
21. 2 synthetase inhibitor, on crescentic nephritis in rats. Eur. J. Pharmacol. 259:1994;233-242.
22. Nahas M.A. Growth factors and glomerular sclerosis. Kidney Int. 41:1992;S15-S20. Suppl. 36.
23. Neuringer J.R., Brenner B.M. Hemodynamic theory of progressive renal disease. A 10-year update in brief review. Am. J. Kidney Dis. 22:1993;98-104.
24. Ots M., Mackzie H.S., Troy J.L., Rennke H.G., Brenner B.M. Effects of combination therapy with enalapril and losartan on the rate of progression of renal injury in rats with 5/6 renal mass ablation. J. Am. Soc. Nephrol. 9:1998;224-230.
25. Ray P.E., Aguilera G., Kopp J.B., Horikoshi S., Klotman P.E. Angiotensin II receptor-mediated proliferation of cultured human fetal mesangial cells. Kidney Int. 40:1991;764-771.
26. 1 receptors. Kidney Int. 45:1994;177-184.
27. Remuzzi A., Perticucci E., Ruggenenti P., Mosconi L., Limonta M., Remuzzi G. Angiotensin converting enzyme inhibition improves glomerular size-selectivity in IgA nephropathy. Kidney Int. 39:1991;1267-1273.
28. Remuzzi A., Ruggenenti P., Mosconi L., Pata V., Viberti G., Remuzzi G. Effect of low-dose enalapril on glomerular size-selectivity in human diabetic nephropathy. J. Nephrol. 6:1993;36-43.
29. Roberts A.B., McCune B.K., Sporn M.B. TGF-β regulation of extracellular matrix. Kidney Int. 41:1992;557-559.
30. Rosen, S., 1983. Classification of glomerular disease. In: The Pathology of Glomerular Disease. Rosen, S. (Ed.). Livingstone, New York, NY, pp. 1-10.
31. Rovin B.H., Rumancik M., Tan L., Dickerson J. Glomerular expression of monocyte chemoattractant protein-1 in experimental and human glomerulonephritis. Lab. Invest. 71:1994;536-542.
32. Ruiz-Ortega M., Gonzalez S., Seron D., Condom E., Bustos C., Largo R., Gonzalez E., Ortiz A., Egido J. ACE inhibition reduces proteinuria, glomerular lesions and extracellular matrix production in a normotensive rat model of immune complex nephritis. Kidney Int. 48:1995;1778-1791.
33. Sady S.P., Goyal M., Thomas P.E., Wharram B.L., Wiggins R.C. Fibronectin mRNA in the developing glomerular crescent in rabbit antiglomerular basement membrane disease. J. Am. Soc. Nephrol. 5:1995;2087-2090.
34. Savage S., Schreier R.W. Progressive renal insufficiency: the role of angiotensin converting enzyme inhibitors. Adv. Int. Med. 37:1991;85-101.
35. Sechi L.A., Grady E.F., Griffin C.A., Kalinyak J.E., Schambelan M. Distribution of angiotensin II receptor subtype in rat and human kidney. Am. J. Physiol. 262:1992;F236-F240.
36. Suzuki Y., Nagamatsu T., Ito M. Pharmacological studies on experimental nephritic rats (5). Studies on experimental nephritis in spontaneously hypertensive rats. Pharmacometrics. 16:1978;249-257.
37. Suzuki Y., Ito M., Saito N. Studies on mechanisms of antinephritic action of SA-446, an angiotensin I converting enzyme inhibitor (1). A comparison with actions of spironolactone, kallidinogenase and saralacin. Jpn. J. Pharmacol. 42:1986;465-475.
38. Wenzel U., Schneider A., Valente A.J., Abboud H.E., Thaiss F., Helmchen U.M., Stahl R.A. Monocyte chemoattractant protein-1 mediates monocyte/macrophage influx in anti-thymocyte antibody-induced glomerulonephritis. Kidney Int. 51:1997;770-776.
39. Wilson H.M., Haites N.E., Booth N.A. Effect of angiotensin II on plasminogen activator inhibitor-1 production by cultured human mesangial cells. Nephron. 77:1997;197-204.
40. Wolf G., Neilson E.G. Angiotensin II as a renal growth factor. J. Am. Soc. Nephrol. 3:1993;1531-1540.
41. 1-receptor antagonist abolish glomerular MCP-1 expression in a model of mesangial proliferative glomerulonephritis. Exp. Nephrol. 6:1998;112-120.
42. Yamamoto T., Noble N.A., Miller D.E., Border W.A. Sustained expression of TGF-β1 underlies development of progressive kidney fibrosis. Kidney Int. 45:1994;916-927.
43. Yayama K., Matsui T., Takano M., Hayashi K., Nagamatsu T., Suzuki Y., Okamoto H. Activation of renin-angiotensin system in anti-glomerular basement membrane antibody-induced glomerulonephritis. Biol. Pharm. Bull. 3:1995;411-415.
44. Yayama K., Makino J., Takano M., Okamoto H. Role of angiotensin II in the transforming growth factor-β1 expression of rat kidney in anti-glomerular basement membrane antiserum-induced glomerulonephritis. Biol. Pharm. Bull. 18:1995;687-690.
45. Zoja C., Abbate M., Corna D., Capitanio M., Donadelli R., Bruzzi I., Oldroyd S., Benigni A., Remuzzi Z. Pharmacologic control of angiotensin II ameliorates renal disease while reducing renal TGF-β in experimental mesangioproliferative glomerulonephritis. Am. J. Kidney Dis. 31:1998;453-463.